

Hepatitis B Virus Resistance to Nucleos(t)ide Analogues

Gastroenterology

137, 1593-1608.e2

DOI: [10.1053/j.gastro.2009.08.063](https://doi.org/10.1053/j.gastro.2009.08.063)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology and Hepatology, 2009, 3, 693-699.	1.4	2
2	Molecular Genetics of HBV Infection. Antiviral Therapy, 2010, 15, 3-14.	0.6	139
3	Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antiviral Therapy, 2010, 15, 1185-1190.	0.6	33
4	Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antiviral Therapy, 2010, 15, 445-449.	0.6	55
5	Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antiviral Therapy, 2010, 15, 529-535.	0.6	13
6	Coevolution and HBV drug resistance. Antiviral Therapy, 2010, 15, 505-515.	0.6	31
7	Infectivity and vaccination efficacy studies in animal models of HBV S and pol gene mutants. Antiviral Therapy, 2010, 15, 477-485.	0.6	9
8	Synthesis and antitumor activity of novel 2- β -diethanethio-2,3,5-trideoxy-5-triazolonucleoside analogues. European Journal of Medicinal Chemistry, 2010, 45, 3219-3222.	2.6	13
9	Viral Resistance in Hepatitis B: Prevalence and Management. Current Gastroenterology Reports, 2010, 12, 62-69.	1.1	7
10	HBV Drug Resistance Development, Testing, and Prevention. Current Hepatitis Reports, 2010, 9, 223-230.	0.3	1
11	The Role of Interferon in Hepatitis B Therapy. Current Hepatitis Reports, 2010, 9, 231-238.	0.3	37
12	Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) Infection. Pharmaceutical Research, 2010, 27, 1184-1202.	1.7	25
13	Efficacy compared between entecavir and adefovir dipivoxil on HBeAg-positive nucleos(t)ide-naïve patients with chronic hepatitis B at week 12 and week 48. Journal of Medical Colleges of PLA, 2010, 25, 298-306.	0.1	0
16	Heparin sulphate d-glucosaminyl 3-O-sulfotransferase 3B1 plays a role in HBV replication. Virology, 2010, 406, 280-285.	1.1	18
17	Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options. Hepatology, 2010, 52, 2192-2205.	3.6	129
18	Transmission of antiviral drug resistant hepatitis B virus: Implications for public health and patient management. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 649-651.	1.4	11
19	Selection and Counterselection of the rtI233V Adefovir Resistance Mutation during Antiviral Therapy. Journal of Clinical Microbiology, 2010, 48, 631-634.	1.8	20
20	Safety evaluation of telbivudine. Expert Opinion on Drug Safety, 2010, 9, 821-829.	1.0	25

#	ARTICLE	IF	CITATIONS
21	Impairment of Hepatitis B Virus Virion Secretion by Single-Amino-Acid Substitutions in the Small Envelope Protein and Rescue by a Novel Glycosylation Site. <i>Journal of Virology</i> , 2010, 84, 12850-12861.	1.5	98
22	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. <i>Viruses</i> , 2010, 2, 2696-2739.	1.5	35
23	Sensitive Assay for Quantification of Hepatitis B Virus Mutants by Use of a Minor Groove Binder Probe and Peptide Nucleic Acids. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4487-4494.	1.8	9
24	End points of therapy in chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 37-49.	1.4	3
25	Drug Resistance in Antiviral Therapy. <i>Clinics in Liver Disease</i> , 2010, 14, 439-459.	1.0	27
26	Discovery and Development of Anti-HBV Agents and Their Resistance. <i>Molecules</i> , 2010, 15, 5878-5908.	1.7	48
27	Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2010, 139, 1207-1217.e3.	0.6	133
28	Acute hepatitis B infection associated with drug-resistant hepatitis B virus. <i>Journal of Clinical Virology</i> , 2010, 48, 270-274.	1.6	45
29	Hepatitis B virus: From diagnosis to treatment. <i>Pathologie Et Biologie</i> , 2010, 58, 245-253.	2.2	40
30	Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. <i>Gut</i> , 2011, 60, 247-254.	6.1	168
31	Network of coordinated substitutions in the Hepatitis B virus polymerase. , 2011, , .		0
32	Treatment failure in chronic hepatitis B. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 366-367.	8.2	10
33	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011, 43, 259-265.	0.4	29
34	The life cycle of hepatitis B virus and antiviral targets. <i>Future Virology</i> , 2011, 6, 599-614.	0.9	11
35	Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients. <i>Clinica Chimica Acta</i> , 2011, 412, 305-313.	0.5	12
37	Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges. <i>Journal of Hepatology</i> , 2011, 54, 1286-1296.	1.8	117
38	Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. <i>Vaccine</i> , 2011, 29, 3909-3916.	1.7	17
39	Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice. <i>Vaccine</i> , 2011, 29, 6342-6351.	1.7	32

#	ARTICLE	IF	CITATIONS
40	Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. <i>Digestive and Liver Disease</i> , 2011, 43, 975-983.	0.4	28
41	Easy-to-use phylogenetic analysis system for hepatitis B virus infection. <i>Hepatology Research</i> , 2011, 41, 936-945.	1.8	7
42	Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. <i>Hepatology Research</i> , 2011, 41, 1017-1024.	1.8	26
43	Hepatitis B Virus (HBV) Variants in Hemodialysis Patients. , 2011, , .		0
44	Boceprevir in the treatment of chronic hepatitis C virus infection. <i>Virus Adaptation and Treatment</i> , 2011, , 7.	1.5	2
45	HBV primary drug resistance in newly diagnosed HIV-1/2-coinfected individuals in Spain. <i>Antiviral Therapy</i> , 2011, 16, 585-589.	0.6	18
46	High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 900-905.	1.1	11
48	High-Resolution Melting and Real-Time Pcr for Quantification and Detection of Drug-Resistant HBV Mutants in a Single Amplicon. <i>Antiviral Therapy</i> , 2012, 17, 291-303.	0.6	9
49	Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 501-513.	1.9	34
50	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 424-431.	1.9	20
51	Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2011, 18, e29-39.	1.0	52
52	Adefovir serum levels do not differ between responders and nonresponders. <i>Journal of Viral Hepatitis</i> , 2011, 18, e175-8.	1.0	1
53	Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, e212-6.	1.0	39
54	Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. <i>Journal of Viral Hepatitis</i> , 2011, 18, e475-e481.	1.0	15
55	Hepatitis B virus resistance to antiviral drugs: where are we going?. <i>Liver International</i> , 2011, 31, 111-116.	1.9	118
56	Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. <i>Journal of Virological Methods</i> , 2011, 171, 67-73.	1.0	14
57	Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array. <i>Journal of Virological Methods</i> , 2011, 175, 1-6.	1.0	9
58	Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis. <i>Virology Journal</i> , 2011, 8, 75.	1.4	6

#	ARTICLE	IF	CITATIONS
59	Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. <i>Antiviral Research</i> , 2011, 89, 109-114.	1.9	12
60	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. <i>Antiviral Research</i> , 2011, 92, 90-95.	1.9	22
61	The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. <i>Antiviral Research</i> , 2011, 92, 271-276.	1.9	75
62	Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. <i>Antiviral Research</i> , 2011, 92, 382-385.	1.9	19
63	HBV life cycle and novel drug targets. <i>Hepatology International</i> , 2011, 5, 644-653.	1.9	97
64	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011, 10, 235-243.	0.3	25
65	Hepatitis B virus Resistance to Antivirals : Diagnosis and Management. <i>Current Hepatitis Reports</i> , 2011, 10, 244-254.	0.3	0
66	Virologic and clinical characteristics of HBV genotypes/subgenotypes in 487 Chinese pediatric patients with CHB. <i>BMC Infectious Diseases</i> , 2011, 11, 262.	1.3	18
68	Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection. <i>Journal of Medical Virology</i> , 2011, 83, 1530-1536.	2.5	22
69	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011, 54, 443-451.	3.6	150
71	A Tyr Residue in the Reverse Transcriptase Domain Can Mimic the Protein-Priming Tyr Residue in the Terminal Protein Domain of a Hepadnavirus P Protein. <i>Journal of Virology</i> , 2011, 85, 7742-7753.	1.5	21
72	A conserved arginine residue in the terminal protein domain of hepatitis B virus polymerase is critical for RNA pre-genome encapsidation. <i>Journal of General Virology</i> , 2011, 92, 1809-1816.	1.3	14
73	A High Level of Mutation Tolerance in the Multifunctional Sequence Encoding the RNA Encapsidation Signal of an Avian Hepatitis B Virus and Slow Evolution Rate Revealed by In Vivo Infection. <i>Journal of Virology</i> , 2011, 85, 9300-9313.	1.5	10
74	Immune and Viral Profile from Tolerance to Hepatitis B Surface Antigen Clearance: a Longitudinal Study of Vertically Hepatitis B Virus-Infected Children on Combined Therapy. <i>Journal of Virology</i> , 2011, 85, 2416-2428.	1.5	56
75	Improved Method for Rapid and Efficient Determination of Genome Replication and Protein Expression of Clinical Hepatitis B Virus Isolates. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1226-1233.	1.8	12
76	Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 39-48.	1.3	17
77	Carbonyl J Acid Derivatives Block Protein Priming of Hepadnaviral P Protein and DNA-Dependent DNA Synthesis Activity of Hepadnaviral Nucleocapsids. <i>Journal of Virology</i> , 2012, 86, 10079-10092.	1.5	21
78	Chronic Viral and Autoimmune Hepatitis. , 2012, , 973-979.		2

#	ARTICLE	IF	CITATIONS
79	New challenges in viral hepatitis. <i>Gut</i> , 2012, 61, i1-i5.	6.1	24
80	Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4277-4288.	1.4	194
83	Lamivudine plus Adefovir or Telbivudine plus Adefovir for Chronic Hepatitis B Patients with Suboptimal Response to Adefovir. <i>Antiviral Therapy</i> , 2012, 17, 973-979.	0.6	11
84	Strong Antiviral Activity of the New L-Hydroxycytidine Derivative, <scp>L</scp>-HYD4FC, In HBV-Infected Human Chimeric UPA/SCID Mice. <i>Antiviral Therapy</i> , 2012, 17, 623-631.	0.6	10
85	Consequences of persistent HBV infection in HIV: the double-edged sword of nucleos(t)ide analogs. <i>Future Virology</i> , 2012, 7, 139-148.	0.9	1
86	Management of treatment failure in chronic hepatitis B. <i>Journal of Hepatology</i> , 2012, 56, S112-S122.	1.8	116
87	Prevention and management of drug resistant hepatitis B virus infections. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1432-1440.	1.4	12
88	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 352-365.	2.6	35
89	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 341-353.	4.6	127
90	Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. <i>Clinical and Experimental Medicine</i> , 2012, 12, 159-164.	1.9	44
91	Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. <i>Liver International</i> , 2012, 32, 1138-1145.	1.9	57
92	Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. <i>Clinical Microbiology and Infection</i> , 2012, 18, E404-E411.	2.8	22
93	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. <i>Journal of Hepatology</i> , 2012, 56, 520-526.	1.8	114
94	Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. <i>Journal of Hepatology</i> , 2012, 56, 1269-1275.	1.8	14
95	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. <i>Journal of Hepatology</i> , 2012, 56, 1254-1258.	1.8	29
96	EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2012, 57, 167-185.	1.8	2,784
97	Focus. <i>Journal of Hepatology</i> , 2012, 56, 1219-1220.	1.8	1
98	Chronic hepatitis B in children and adolescents. <i>Journal of Hepatology</i> , 2012, 57, 885-896.	1.8	72

#	ARTICLE	IF	CITATIONS
100	New natural variants of hepatitis B virus among Amerindians from Argentina with mainly occult infections. <i>Journal of Clinical Virology</i> , 2012, 54, 174-179.	1.6	22
101	Preventing Perinatal Transmission of HBV: An Australian Perspective. <i>Current Hepatitis Reports</i> , 2012, 11, 206-212.	0.3	2
102	Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. <i>Hepatology</i> , 2012, 56, 1706-1718.	3.6	34
103	Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: A 5-year study of patients with hepatitis B with lamivudine resistance. <i>Journal of Medical Virology</i> , 2012, 84, 1562-1570.	2.5	4
104	Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. <i>BMC Microbiology</i> , 2012, 12, 96.	1.3	18
105	Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 683-694.	1.4	20
106	Is Hepatitis Virus Resistance to Antiviral Drugs a Threat?. <i>Gastroenterology</i> , 2012, 142, 1369-1372.	0.6	9
107	Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. <i>Antiviral Research</i> , 2012, 96, 422-429.	1.9	24
108	Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, e89-e92.	0.7	15
109	Convergence and coevolution of Hepatitis B virus drug resistance. <i>Nature Communications</i> , 2012, 3, 789.	5.8	45
110	HBV mutations and their clinical significance. <i>Advances in Medical Sciences</i> , 2012, 57, 18-22.	0.9	15
111	New insight in the pathobiology of hepatitis B virus infection. <i>Gut</i> , 2012, 61, i6-i17.	6.1	190
112	Dynamics of Hepatitis B Virus Quasispecies in Association with Nucleos(t)ide Analogue Treatment Determined by Ultra-Deep Sequencing. <i>PLoS ONE</i> , 2012, 7, e35052.	1.1	76
113	Ultra-Deep Pyrosequencing Detects Conserved Genomic Sites and Quantifies Linkage of Drug-Resistant Amino Acid Changes in the Hepatitis B Virus Genome. <i>PLoS ONE</i> , 2012, 7, e37874.	1.1	49
114	Diagnostic incidence of the presence of positive HBsAg: epidemiologic, clinical, and virological characteristics. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 10-15.	0.1	11
115	Extensive Mutagenesis of the Conserved Box E Motif in Duck Hepatitis B Virus P Protein Reveals Multiple Functions in Replication and a Common Structure with the Primer Grip in HIV-1 Reverse Transcriptase. <i>Journal of Virology</i> , 2012, 86, 6394-6407.	1.5	17
116	Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. <i>Hepatology</i> , 2012, 56, 434-443.	3.6	116
117	Viral Quasispecies Evolution. <i>Microbiology and Molecular Biology Reviews</i> , 2012, 76, 159-216.	2.9	811

#	ARTICLE	IF	CITATIONS
118	Partial Response to Entecavir and Tenofovir in Na ⁺ ve Patients with Chronic Hepatitis B: Clinical Relevance and Management. <i>Current Hepatitis Reports</i> , 2012, 11, 90-94.	0.3	5
119	Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2012, 11, 55-64.	0.3	1
120	Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 306-312.	1.4	37
121	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2877-2888.	1.4	24
122	Synthesis, biological evaluation and structure-activity relationships of glycyrrhetic acid derivatives as novel anti-hepatitis B virus agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3473-3479.	1.0	51
123	Treatment of human immunodeficiency virus and hepatitis B virus infections. <i>Haemophilia</i> , 2012, 18, 34-37.	1.0	1
124	Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2012, 19, 220-226.	1.0	28
125	Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. <i>Virology Journal</i> , 2013, 10, 162.	1.4	13
126	Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2013, 12, 251-255.	0.6	10
127	Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1987-1996.	1.2	25
128	Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype. <i>Hepatology International</i> , 2013, 7, 443-450.	1.9	10
129	Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2013, 48, 1188-1204.	2.3	70
130	Resistance is no Longer a Problem with Entecavir and Tenofovir. <i>Current Hepatitis Reports</i> , 2013, 12, 96-104.	0.3	0
131	Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir. <i>Science Bulletin</i> , 2013, 58, 1760-1766.	1.7	7
132	Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines. <i>Journal of Hepatology</i> , 2013, 59, 814-829.	1.8	178
133	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. <i>Journal of Infection</i> , 2013, 67, 322-328.	1.7	26
134	The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. <i>Journal of Hepatology</i> , 2013, 58, 861-867.	1.8	286
135	Chronic Hepatitis B in Children and Adolescents: Epidemiology and Management. <i>Paediatric Drugs</i> , 2013, 15, 311-317.	1.3	21

#	ARTICLE	IF	CITATIONS
136	Influence of Age and HBeAg Status on the Correlation Between HBV DNA and Hepatic Inflammation and Fibrosis in Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1355-1362.	1.1	13
137	Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients. <i>Journal of General Virology</i> , 2013, 94, 2729-2738.	1.3	8
138	How further suppression of virus replication could improve current HBV treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 755-757.	2.0	11
139	Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection. <i>Annual Reports in Medicinal Chemistry</i> , 2013, 48, 265-281.	0.5	7
140	Hepatitis B virus genetic variants: biological properties and clinical implications. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-11.	3.0	47
141	Analysis of Mutations in the <i>S</i> Gene of Hepatitis B Virus Strains in Patients with Chronic Infection by Online Bioinformatics Tools. <i>Journal of Clinical Microbiology</i> , 2013, 51, 163-168.	1.8	15
142	Experimental models and therapeutic approaches for HBV. <i>Seminars in Immunopathology</i> , 2013, 35, 7-21.	2.8	34
143	Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy. <i>Journal of Medical Virology</i> , 2013, 85, 55-64.	2.5	19
144	How to manage HBeAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice?. <i>European Journal of Internal Medicine</i> , 2013, 24, 100-103.	1.0	8
146	389 ENHANCING VIRUS-SPECIFIC IMMUNITY IN VIVO BY COMBINING THERAPEUTIC VACCINATION AND PD1/PD-L1 BLOCKADE IN CHRONIC HEPADNAVIRAL INFECTION. <i>Journal of Hepatology</i> , 2013, 58, S160.	1.8	0
147	Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. <i>Journal of Hepatology</i> , 2013, 59, 684-695.	1.8	24
148	Î²-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. <i>Antiviral Research</i> , 2013, 99, 221-229.	1.9	85
149	Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. <i>Journal of Hepatology</i> , 2013, 58, 212-216.	1.8	31
150	Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. <i>Journal of Clinical Virology</i> , 2013, 58, 67-73.	1.6	39
151	Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. <i>Liver International</i> , 2013, 33, 116-124.	1.9	56
153	Anti-HBV agents derived from botanical origin. <i>FÄ-toterapÄ-Äç</i> , 2013, 84, 140-157.	1.1	34
155	Methods for Monitoring Gene Gun-Induced HBV- and HCV-Specific Immune Responses in Mouse Models. <i>Methods in Molecular Biology</i> , 2013, 940, 239-267.	0.4	6
156	Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 447-464.	21.5	925

#	ARTICLE	IF	CITATIONS
157	Influence of overlapping genes on the evolution of human hepatitis B virus. <i>Virology</i> , 2013, 441, 40-48.	1.1	30
158	High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. <i>Hepatology</i> , 2013, 58, 912-922.	3.6	37
159	Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. <i>Hepatology</i> , 2013, 58, 43-53.	3.6	102
160	Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. <i>Future Virology</i> , 2013, 8, 371-380.	0.9	110
161	Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance. <i>Hepatitis Monthly</i> , 2013, 13, e12160.	0.1	5
162	Stimulation of dendritic cells with vaccine and vaccine-antibody complex and effect on immune response. <i>Turkish Journal of Biology</i> , 2013, 37, 457-463.	2.1	1
163	The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes. <i>PLoS Pathogens</i> , 2013, 9, e1003125.	2.1	96
164	Mutation Reporter Tool: An online tool to interrogate loci of interest, with its utility demonstrated using hepatitis B virus. <i>Virology Journal</i> , 2013, 10, 62.	1.4	15
165	Phase Diagrams Map the Properties of Antiviral Agents Directed against Hepatitis B Virus Core Assembly. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1505-1508.	1.4	30
166	Noncompetitive Inhibition of Hepatitis B Virus Reverse Transcriptase Protein Priming and DNA Synthesis by the Nucleoside Analog Clevudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4181-4189.	1.4	40
167	HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion. <i>Journal of Virology</i> , 2013, 87, 10313-10323.	1.5	109
168	Sulfamoylbenzamide Derivatives Inhibit the Assembly of Hepatitis B Virus Nucleocapsids. <i>Journal of Virology</i> , 2013, 87, 6931-6942.	1.5	154
169	HBVdb: a knowledge database for Hepatitis B Virus. <i>Nucleic Acids Research</i> , 2013, 41, D566-D570.	6.5	178
170	Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. <i>Clinical Infectious Diseases</i> , 2013, 56, 1812-1819.	2.9	61
171	Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 321-326.	0.7	24
172	Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. <i>Journal of Medical Virology</i> , 2013, 85, 996-1004.	2.5	19
173	High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates. <i>Journal of Medical Virology</i> , 2013, 85, 775-779.	2.5	11
174	Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. <i>Hepatology</i> , 2013, 58, 890-901.	3.6	59

#	ARTICLE	IF	CITATIONS
175	Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-11.	3.0	79
176	A modified murine model based on hydrodynamic injection for the analysis of chronic human hepatitis B virus infection. <i>Molecular Medicine Reports</i> , 2013, 8, 1677-1682.	1.1	1
177	Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil. <i>Virology Journal</i> , 2013, 10, 320.	1.4	10
178	Efficacy and safety of peginterferon alfa-2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B. <i>Antiviral Therapy</i> , 2013, 18, 765-773.	0.6	5
179	A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus. <i>International Journal of Molecular Medicine</i> , 2013, 31, 975-981.	1.8	3
180	Variables determining the virologic response to adefovir treatment in patients with chronic HBV infection previously treated with lamivudine. <i>African Journal of Microbiology Research</i> , 2013, 7, 1-6.	0.4	1
181	Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine. <i>Antiviral Therapy</i> , 2013, 18, 671-680.	0.6	8
182	Hepatitis B virus part 2: treatment options and the role of the specialist nurse. <i>Gastrointestinal Nursing</i> , 2013, 11, 33-40.	0.0	0
183	Novel Natural Mutations in the Hepatitis B Virus Reverse Transcriptase Domain Associated with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e94864.	1.1	16
184	Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e98865.	1.1	56
185	Differential Binding of Tenofovir and Adefovir to Reverse Transcriptase of Hepatitis B Virus. <i>PLoS ONE</i> , 2014, 9, e106324.	1.1	19
186	Mutations in Pol gene of hepatitis B virus in patients with chronic hepatitis B before and after therapy with nucleoside/nucleotide analogues. <i>Acta Virologica</i> , 2014, 58, 185-189.	0.3	3
187	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. <i>Drug Design, Development and Therapy</i> , 2014, 8, 869.	2.0	9
188	Update on hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 13293.	1.4	64
189	Selected Phenotypic Assays Used to Evaluate Antiviral Resistance and Viral Fitness of Hepatitis B Virus and Its Variants. <i>Intervirolgy</i> , 2014, 57, 225-231.	1.2	7
190	Mechanisms of Hepatitis B Virus Resistance Development. <i>Intervirolgy</i> , 2014, 57, 218-224.	1.2	22
191	<i>In vitro</i> Immunomodulatory Activity of Oxymatrine on Toll-Like Receptor 9 Signal Pathway in Chronic Hepatitis B. <i>The American Journal of Chinese Medicine</i> , 2014, 42, 1399-1410.	1.5	27
192	Hepatitis B Virus Drug Resistance Tools: One Sequence, Two Predictions. <i>Intervirolgy</i> , 2014, 57, 232-236.	1.2	26

#	ARTICLE	IF	CITATIONS
193	Clinical implications of hepatitis B virus mutations: Recent advances. <i>World Journal of Gastroenterology</i> , 2014, 20, 7653.	1.4	120
194	Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection. <i>PLoS Pathogens</i> , 2014, 10, e1003856.	2.1	231
195	Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. <i>Mathematical Medicine and Biology</i> , 2015, 32, dqu022.	0.8	1
196	Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. <i>Journal of Viral Hepatitis</i> , 2014, 21, 809-817.	1.0	61
197	Amino acid polymorphism in the reverse transcriptase region of hepatitis B virus and the relationship with nucleos(t)ide analogues treatment for preventing mother-to-infant transmission. <i>Journal of Medical Virology</i> , 2014, 86, 1288-1295.	2.5	6
198	Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 364-381.	1.0	17
199	Prevalence mutations of hepatitis B virus affect genome replication and expression of surface antigens. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 843-850.	1.4	7
200	miR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene. <i>Archives of Virology</i> , 2014, 159, 3335-3343.	0.9	32
201	Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 146-154.	0.8	7
202	Structurally Similar Woodchuck and Human Hepadnavirus Core Proteins Have Distinctly Different Temperature Dependences of Assembly. <i>Journal of Virology</i> , 2014, 88, 14105-14115.	1.5	27
203	SASLT practice guidelines for the management of hepatitis B virus. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 5.	0.5	27
204	High-Throughput Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry as an Alternative Approach to Monitoring Drug Resistance of Hepatitis B Virus. <i>Journal of Clinical Microbiology</i> , 2014, 52, 9-14.	1.8	10
205	JSH Guidelines for the Management of Hepatitis B Virus Infection. <i>Hepatology Research</i> , 2014, 44, 1-58.	1.8	142
206	Mutations in HBV DNA Polymerase Associated With Nucleos(t)ide Resistance Are Rare in Treatment-naïve Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1363-1370.	2.4	24
207	Recent insights into hepatitis B virus-host interactions. <i>Journal of Medical Virology</i> , 2014, 86, 925-932.	2.5	22
208	Support of the Infectivity of Hepatitis Delta Virus Particles by the Envelope Proteins of Different Genotypes of Hepatitis B Virus. <i>Journal of Virology</i> , 2014, 88, 6255-6267.	1.5	21
209	Systemic diseases and biotherapies: Understanding, evaluating, and preventing the risk of hepatitis B reactivation. <i>Joint Bone Spine</i> , 2014, 81, 478-484.	0.8	23
210	Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes. <i>Gastroenterology</i> , 2014, 147, 48-64.	0.6	293

#	ARTICLE	IF	CITATIONS
211	Hepatitis B virus PreS/S gene variants: Pathobiology and clinical implications. <i>Journal of Hepatology</i> , 2014, 61, 408-417.	1.8	208
213	Comparative Analysis of Hepatitis B Virus Polymerase Sequences Required for Viral RNA Binding, RNA Packaging, and Protein Priming. <i>Journal of Virology</i> , 2014, 88, 1564-1572.	1.5	35
214	New therapeutic vaccination strategies for the treatment of chronic hepatitis B. <i>Virologica Sinica</i> , 2014, 29, 10-16.	1.2	44
215	Ultradeep Pyrosequencing and Molecular Modeling Identify Key Structural Features of Hepatitis B Virus RNase H, a Putative Target for Antiviral Intervention. <i>Journal of Virology</i> , 2014, 88, 574-582.	1.5	10
216	Management of chronic hepatitis B in children: An unresolved issue. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 912-919.	1.4	32
217	Incidence and risk factors for incomplete HBV DNA suppression in HIV/ HBV-infected patients initiating tenofovir-based therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 288-296.	1.0	20
218	Long-Term Efficacy of Entecavir Plus Adefovir Combination Therapy versus Entecavir Monotherapy in Adefovir Refractory Chronic Hepatitis B Patients with Prior Lamivudine Resistance. <i>Intervirolgy</i> , 2014, 57, 8-16.	1.2	8
219	A simple and efficient strategy for the de novo construction of greater-than-genome-length hepatitis B virus replicons. <i>Journal of Virological Methods</i> , 2014, 207, 158-162.	1.0	3
220	The Impact of the Hepatitis B Virus Polymerase rtA181T Mutation on Replication and Drug Resistance Is Potentially Affected by Overlapping Changes in Surface Gene. <i>Journal of Virology</i> , 2014, 88, 6805-6818.	1.5	32
221	Molecular epidemiology of Hepatitis B virus in Córdoba, Argentina. <i>Journal of Clinical Virology</i> , 2014, 61, 204-210.	1.6	12
222	Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4244-53.	3.3	193
223	Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. <i>Journal of Hepatology</i> , 2014, 61, 502-507.	1.8	152
224	Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. <i>Acta Pharmaceutica Sinica B</i> , 2014, 4, 248-257.	5.7	48
225	Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus. <i>Journal of Virological Methods</i> , 2014, 201, 51-56.	1.0	5
226	Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. <i>Antiviral Research</i> , 2014, 108, 48-55.	1.9	63
227	Screening and identification of a novel adefovir dipivoxil-resistance-associated mutation rtN236V of HBV from a large cohort of HBV-infected patients. <i>Antiviral Therapy</i> , 2014, 19, 551-558.	0.6	11
228	Investigation into drug-resistant mutations of HBV from 845 nucleos(t)ide analogue-naive Chinese patients with chronic HBV infection. <i>Antiviral Therapy</i> , 2014, 20, 141-147.	0.6	15
229	Could inhibiting IL-8 enhance HBV IFN- λ treatment?. <i>Future Virology</i> , 2014, 9, 1015-1017.	0.9	0

#	ARTICLE	IF	CITATIONS
230	Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China. <i>Scientific Reports</i> , 2015, 5, 17413.	1.6	27
231	Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. <i>Scientific Reports</i> , 2015, 5, 17123.	1.6	14
232	HBV Carrying Drug-Resistance Mutations in Chronically Infected Treatment-Naive Patients. <i>Antiviral Therapy</i> , 2015, 20, 387-395.	0.6	31
233	High Incidence of Lamivudine-Resistance-Associated Vaccine-Escape HBV Mutants among HIV-Coinfected Patients on Prolonged Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2015, 20, 545-554.	0.6	14
234	Entecavir Allows an Unexpectedly High Residual Replication of HBV Mutants Resistant to Lamivudine. <i>Antiviral Therapy</i> , 2015, 20, 779-787.	0.6	11
235	Naturally occurring deletions/insertions in HBV core promoter tend to decrease in HBeAg-positive chronic hepatitis B patients during antiviral therapy. <i>Antiviral Therapy</i> , 2015, 20, 623-632.	0.6	14
238	Rethinking the pathogenesis of hepatitis B virus (HBV) infection. <i>Journal of Medical Virology</i> , 2015, 87, 1989-1999.	2.5	36
239	The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 255-259.	0.8	44
240	Hepatitis B. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 557-562.	1.3	7
241	Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin. <i>Transplant Infectious Disease</i> , 2015, 17, 208-220.	0.7	9
242	Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B. <i>Journal of Medical Virology</i> , 2015, 87, 1527-1531.	2.5	3
243	Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus. <i>Liver International</i> , 2015, 35, 2265-2274.	1.9	2
244	Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures. <i>Journal of Medical Virology</i> , 2015, 87, 1013-1021.	2.5	4
245	Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1514-1521.	1.4	11
246	Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. <i>International Journal of Medical Sciences</i> , 2015, 12, 416-422.	1.1	4
247	Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 417.	0.9	1
248	Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus. <i>PLoS ONE</i> , 2015, 10, e0145746.	1.1	5
249	Development of a novel hepatitis B virus encapsidation detection assay by viral nucleocapsid-captured quantitative RT-PCR. <i>BioTechniques</i> , 2015, 59, 287-93.	0.8	2

#	ARTICLE	IF	CITATIONS
250	Superinfection with Woodchuck Hepatitis Virus Strain WHVNY of Livers Chronically Infected with Strain WHV7. <i>Journal of Virology</i> , 2015, 89, 384-405.	1.5	13
251	A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response. <i>Infection, Genetics and Evolution</i> , 2015, 33, 269-276.	1.0	3
252	HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. <i>Gut</i> , 2015, 64, 1972-1984.	6.1	659
253	Capacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks. <i>Virus Research</i> , 2015, 205, 12-21.	1.1	4
254	Antiviral Therapies and Prospects for a Cure of Chronic Hepatitis B. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021501-a021501.	2.9	128
255	Impact of Nucleos(t)ide Analogue Combination Therapy on the Estimated Glomerular Filtration Rate in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2015, 94, e646.	0.4	14
256	Efficacy of tenofovir disoproxil fumarate therapy in Chinese chronic hepatitis B patients after multiple antiviral failures. <i>Hepatology Research</i> , 2015, 45, E43-52.	1.8	1
257	Molecular characterisation of hepatitis B virus in HIV-1 subtype C infected patients in Botswana. <i>BMC Infectious Diseases</i> , 2015, 15, 335.	1.3	16
258	Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5348-5356.	1.4	7
259	Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?. <i>Liver International</i> , 2015, 35, 114-120.	1.9	18
260	Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?. <i>Medical Microbiology and Immunology</i> , 2015, 204, 121-129.	2.6	23
261	Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	6.1	234
262	Transbody against hepatitis B virus core protein inhibits hepatitis B virus replication in vitro. <i>International Immunopharmacology</i> , 2015, 25, 363-369.	1.7	7
263	Hepatitis B vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 53-57.	1.4	79
264	The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2015, 87, 575-582.	2.5	14
265	Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 252-261.	1.4	28
266	Clinical significance of periodic detection of hepatitis B virus YVDD mutation by ultrasensitive real-time amplification refractory mutation system quantitative PCR during lamivudine treatment in patients with chronic hepatitis B. <i>Journal of Medical Microbiology</i> , 2015, 64, 237-242.	0.7	2
267	Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck. <i>Medical Microbiology and Immunology</i> , 2015, 204, 103-114.	2.6	32

#	ARTICLE	IF	CITATIONS
268	HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. <i>Journal of Hepatology</i> , 2015, 63, 1093-1102.	1.8	161
269	Optimal management of hepatitis B virus infection – EASL Special Conference. <i>Journal of Hepatology</i> , 2015, 63, 1238-1253.	1.8	91
270	Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study). <i>Hepatology</i> , 2015, 61, 1512-1522.	3.6	145
271	Chronic hepatitis B: A wave of new therapies on the horizon. <i>Antiviral Research</i> , 2015, 121, 69-81.	1.9	65
272	Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy. <i>Acta Clinica Belgica</i> , 2015, 70, 223-225.	0.5	5
273	The hepatitis B virus ribonuclease H as a drug target. <i>Antiviral Research</i> , 2015, 118, 132-138.	1.9	59
274	Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. <i>Journal of Hepatology</i> , 2015, 62, S76-S86.	1.8	198
275	Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. <i>Gene</i> , 2015, 567, 22-30.	1.0	1
276	Recent progress for the synthesis of selected carbocyclic nucleosides. <i>Future Medicinal Chemistry</i> , 2015, 7, 1809-1828.	1.1	29
277	New paradigms in hepatitis B management: only diamonds are forever. <i>British Medical Bulletin</i> , 2015, 116, ldv039.	2.7	9
278	Hepatitis B virus reverse transcriptase – Target of current antiviral therapy and future drug development. <i>Antiviral Research</i> , 2015, 123, 132-137.	1.9	70
279	Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2015, 109, 723-729.	0.7	9
280	The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021451.	2.9	20
281	Functional Aspects of Intrahepatic Hepatitis B Virus-specific T Cells Induced by Therapeutic DNA Vaccination. <i>Molecular Therapy</i> , 2015, 23, 578-590.	3.7	13
282	A computational chemistry perspective on the current status and future direction of hepatitis B antiviral drug discovery. <i>Antiviral Research</i> , 2015, 123, 204-215.	1.9	13
283	Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. <i>Antiviral Research</i> , 2015, 122, 91-100.	1.9	122
284	Inhibitory effect of <i>Phyllanthus urinaria</i> L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 255.	3.7	21
286	Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 291-295.	0.3	9

#	ARTICLE	IF	CITATIONS
287	Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "œmagic bullet" to kill cccDNA. <i>Antiviral Research</i> , 2015, 123, 193-203.	1.9	36
288	Safety and immunogenicity of therapeutic <scp>DNA</scp> vaccine with antiviral drug in chronic <scp>HBV</scp> patients and its immunogenicity in mice. <i>Liver International</i> , 2015, 35, 805-815.	1.9	51
289	Hepatitis B virus (<scp>HBV</scp>) variants fluctuate in paired plasma and peripheral blood mononuclear cells among patient cohorts during different chronic hepatitis B (<scp>CHB</scp>) disease phases. <i>Journal of Viral Hepatitis</i> , 2015, 22, 416-426.	1.0	29
290	Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS. <i>Clinical Microbiology and Infection</i> , 2015, 21, 288.e1-288.e4.	2.8	6
291	Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial"ANRS HB02 VAC-ADN. <i>Gut</i> , 2015, 64, 139-147.	6.1	91
292	Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 972-978.	1.4	20
293	Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. <i>Hepatology</i> , 2015, 61, 712-721.	3.6	146
294	Hepatitis B Virus. , 2016, , 713-770.		2
295	Genetic variation of occult hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2016, 22, 3531.	1.4	69
296	Overview of hepatitis B virus mutations and their implications in the management of infection. <i>World Journal of Gastroenterology</i> , 2016, 22, 145.	1.4	121
297	Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-10.	0.7	2
298	Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis. <i>Japanese Journal of Infectious Diseases</i> , 2016, 69, 306-313.	0.5	1
299	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
300	Characterization of hepatitis B virus surface antigen variability and impact on <scp>HB</scp>'s antigen clearance under nucleos(t)ide analogue therapy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 387-398.	1.0	22
301	Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide. <i>Scientific Reports</i> , 2016, 6, 29391.	1.6	11
303	Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2016, 15, 579-586.	0.6	16
304	Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. <i>Hepatology International</i> , 2016, 10, 779-788.	1.9	17
305	Overview of hepatitis B viral replication and genetic variability. <i>Journal of Hepatology</i> , 2016, 64, S4-S16.	1.8	303

#	ARTICLE	IF	CITATIONS
306	Mechanisms of HBV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, S84-S101.	1.8	664
307	Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. <i>Journal of Hepatology</i> , 2016, 64, S17-S31.	1.8	105
308	Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 117-123.	0.8	2
309	Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing. <i>Medicine (United States)</i> , 2016, 95, e2614.	0.4	5
310	Compensatory variances of drug-induced hepatitis B virus YMDD mutations. <i>SpringerPlus</i> , 2016, 5, 1340.	1.2	1
311	Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. <i>Antiviral Research</i> , 2016, 134, 97-107.	1.9	63
312	HBV/4DR 9G test and its comparison with INNO-LiPA HBV multi-DR test for the detection of drug-resistant Hepatitis B virus. <i>Journal of Virological Methods</i> , 2016, 237, 58-63.	1.0	1
313	Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2016, 23, 154-169.	1.0	26
314	Detection of Anti-Hepatitis B Virus Drug Resistance Mutations Based on Multicolor Melting Curve Analysis. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2661-2668.	1.8	4
315	Current molecular methods for the detection of hepatitis B virus quasispecies. <i>Reviews in Medical Virology</i> , 2016, 26, 369-381.	3.9	9
316	Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 2293-2299.	0.8	4
317	Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultra-deep pyrosequencing. <i>Molecular Medicine Reports</i> , 2016, 13, 651-660.	1.1	3
318	Antiviral drug resistance as an adaptive process. <i>Virus Evolution</i> , 2016, 2, vew014.	2.2	162
319	HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia. <i>Antiviral Therapy</i> , 2016, 22, 97-111.	0.6	12
320	Current treatments for chronic hepatitis B virus infections. <i>Current Opinion in Virology</i> , 2016, 18, 109-116.	2.6	70
321	Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation. <i>Journal of Virology</i> , 2016, 90, 7171-7183.	1.5	38
322	EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes. <i>Journal of Hepatology</i> , 2016, 65, 888-898.	1.8	53
323	Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. <i>Journal of Hepatology</i> , 2016, 65, 683-691.	1.8	84

#	ARTICLE	IF	CITATIONS
324	De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 24.	1.7	2
325	Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. <i>Antiviral Research</i> , 2016, 132, 26-37.	1.9	48
326	A strong conservative tendency in <scp>HBV</scp> transcriptase (<scp>RT</scp>): a majority of natural <scp>RT</scp> mutations derived from the S gene. <i>Liver International</i> , 2016, 36, 963-970.	1.9	4
327	Hepatitis B: treatment choice and monitoring for response and resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 697-707.	1.4	11
328	Design and synthesis of pyridine-pyrazole-sulfonate derivatives as potential anti-HBV agents. <i>MedChemComm</i> , 2016, 7, 832-836.	3.5	14
329	Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. <i>Molecular and Translational Medicine</i> , 2016, , 95-121.	0.4	2
330	A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles. <i>Medicine (United States)</i> , 2016, 95, e2511.	0.4	3
331	Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naïve patients with Chronic Hepatitis B in Central China. <i>Brazilian Journal of Infectious Diseases</i> , 2016, 20, 173-178.	0.3	12
333	Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 93-98.	0.4	10
334	Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha. <i>Journal of Natural Medicines</i> , 2016, 70, 584-591.	1.1	38
335	Experimental Models: Cell Culture and Animal Models. <i>Molecular and Translational Medicine</i> , 2016, , 35-62.	0.4	0
336	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. <i>Journal of Infection</i> , 2016, 72, 91-102.	1.7	17
337	Anti-hepatitis B virus effect of matrine-type alkaloid and involvement of p38 mitogen-activated protein kinase and tumor necrosis factor receptor-associated factor 6. <i>Virus Research</i> , 2016, 215, 104-113.	1.1	27
338	An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 177-186.	1.4	7
339	Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory. <i>Journal of Clinical Microbiology</i> , 2016, 54, 127-133.	1.8	25
340	The Basis for Antiviral Therapy: Drug Targets, Cross-Resistance, and Novel Small Molecule Inhibitors. <i>Molecular and Translational Medicine</i> , 2016, , 303-324.	0.4	4
341	Advances in therapeutics for chronic hepatitis B. <i>Hepatology International</i> , 2016, 10, 277-285.	1.9	19
342	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 1042-1051.	6.1	76

#	ARTICLE	IF	CITATIONS
343	The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response. <i>Infection, Genetics and Evolution</i> , 2017, 49, 116-121.	1.0	1
344	Novel targets for hepatitis B virus therapy. <i>Liver International</i> , 2017, 37, 33-39.	1.9	58
345	Entecavir for patients with lamivudine-resistant chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 0, , .	1.5	1
346	The virological aspects of hepatitis B. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 257-264.	1.0	31
347	Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 707-716.	1.3	31
348	Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed <scp>LAM</scp>/<scp>ADV</scp> therapy. <i>Liver International</i> , 2017, 37, 827-835.	1.9	13
349	Differences in sequences between HBV-relaxed circular DNA and covalently closed circular DNA. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	3.0	6
350	Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1032-1042.	1.0	10
351	Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs. <i>Antiviral Therapy</i> , 2017, 23, 33-42.	0.6	5
352	An Effective Antiviral Approach Targeting Hepatitis B Virus with NJK14047, a Novel and Selective Biphenyl Amide p38 Mitogen-Activated Protein Kinase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	16
353	Management of Chronic Hepatitis B in Children. <i>Current Hepatology Reports</i> , 2017, 16, 81-89.	0.4	0
354	HBV Therapy and the Problem of Drug Resistance. , 2017, , 3-20.		1
355	Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. <i>Hepatology</i> , 2017, 66, 772-783.	3.6	37
356	Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naïve chronic hepatitis B patients. <i>BMC Gastroenterology</i> , 2017, 17, 39.	0.8	35
357	The Enrichment of HBV Immune-Escape Mutations during Nucleoside/Nucleotide Analogue Therapy. <i>Antiviral Therapy</i> , 2017, 22, 717-720.	0.6	5
358	HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy. <i>Scientific Reports</i> , 2017, 7, 44742.	1.6	6
359	Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014). <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 74-81.	0.9	13
360	Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 897-909.	1.8	125

#	ARTICLE	IF	CITATIONS
361	In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV RNaseH Inhibitors. <i>Methods in Molecular Biology</i> , 2017, 1540, 179-192.	0.4	5
362	Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2017, 37, 547-555.	1.0	5
363	The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2017, 23, 239-248.	0.6	8
365	How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?. <i>Journal of Hepatology</i> , 2017, 67, 1281-1297.	1.8	132
366	Novel HBV mutations and their value in predicting efficacy of conventional interferon. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 189-196.	0.6	1
367	The US Food and Drug Administration's tentative approval process and the global fight against HIV. <i>Journal of the International AIDS Society</i> , 2017, 20, e25019.	1.2	5
368	Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 29-35.	1.0	11
369	Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. <i>Antiviral Research</i> , 2017, 145, 14-19.	1.9	49
370	Drugs in Development for Hepatitis B. <i>Drugs</i> , 2017, 77, 1263-1280.	4.9	29
371	Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 638-644.	1.0	12
372	Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy. <i>Cytotherapy</i> , 2017, 19, 107-118.	0.3	14
373	Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. <i>Journal of Gastroenterology</i> , 2017, 52, 641-651.	2.3	15
374	Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy. <i>American Journal of Therapeutics</i> , 2017, 24, e250-e258.	0.5	1
375	Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis. <i>Virology</i> , 2017, 501, 70-78.	1.1	11
377	Recent advances in the study of hepatitis B virus covalently closed circular DNA. <i>Virologica Sinica</i> , 2017, 32, 454-464.	1.2	18
378	New Strategy Treating Hepatitis B Virus (HBV) Infection: A Review of HBV Infection Biology. , 0, , .		1
379	New Antiretrovirals for HIV and Antivirals for HBV. , 2017, , 628-664.		1
380	HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. <i>Viruses</i> , 2017, 9, 199.	1.5	2

#	ARTICLE	IF	CITATIONS
381	Hepatitis B virus DNA polymerase gene polymorphism based prediction of genotypes in chronic HBV patients from Western India. <i>African Health Sciences</i> , 2017, 17, 762.	0.3	8
382	Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 91.	1.8	96
383	Protective Effects of <i>Moringa oleifera</i> on HBV Genotypes C and H Transiently Transfected Huh7 Cells. <i>Journal of Immunology Research</i> , 2017, 1-9.	0.9	23
384	Recommendations for the treatment of hepatitis B in 2017. <i>Clinical and Experimental Hepatology</i> , 2017, 2, 35-46.	0.6	15
385	Emtricitabine for adults with lamivudine-resistant chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 2017, . .	1.5	2
386	Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B. <i>Infection and Drug Resistance</i> , 2017, Volume 10, 201-207.	1.1	14
387	Viral hepatitis and hepatocellular carcinoma: etiology and management. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 229-242.	0.6	120
388	Substitutions of rtL228 and/or L229 are involved in the regulation of replication and HBsAg secretion in hepatitis B virus, and do not affect susceptibility to nucleos(t)ide analogs. <i>Molecular Medicine Reports</i> , 2017, 16, 9678-9684.	1.1	5
389	Could resistant and escape variants of hepatitis B virus be a problem in the future?. <i>Future Virology</i> , 2018, 13, 171-179.	0.9	4
390	Asymmetric Modification of Hepatitis B Virus (HBV) Genomes by an Endogenous Cytidine Deaminase inside HBV Cores Informs a Model of Reverse Transcription. <i>Journal of Virology</i> , 2018, 92, .	1.5	26
391	Novel stable HBV producing cell line systems for expression and screening antiviral inhibitor of hepatitis B virus in human hepatoma cell line. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 64-71.	1.0	1
392	Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009–2016: A retrospective study. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 201-209.	1.1	28
393	Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China. <i>Journal of Medical Virology</i> , 2018, 90, 1246-1256.	2.5	7
394	Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation. <i>Antiviral Research</i> , 2018, 154, 26-34.	1.9	13
395	Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. <i>Global Health Action</i> , 2018, 11, 1433987.	0.7	22
396	Discovery of Small Molecule Therapeutics for Treatment of Chronic HBV Infection. <i>ACS Infectious Diseases</i> , 2018, 4, 257-277.	1.8	44
397	Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. , 2018, , 263-296.		0
398	Molecular Virology and Life Cycle. , 2018, , 1-23.		1

#	ARTICLE	IF	CITATIONS
399	Hepatitis B Virus and Liver Disease. , 2018, , .		1
400	Impact of etiological treatment on prognosis. Hepatology International, 2018, 12, 56-67.	1.9	12
401	Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut, 2018, 67, 2181-2191.	6.1	255
402	Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010â€“2016). Virus Genes, 2018, 54, 41-47.	0.7	10
403	Early changes in quasispecies variant after antiviral therapy for chronic hepatitis B. Molecular Medicine Reports, 2018, 17, 5528-5537.	1.1	2
404	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. Gastroenterology Research and Practice, 2018, 2018, 1-9.	0.7	1
405	In Vitro Anti-hepatitis B Virus Activity of 2â€²,3â€²-Dideoxyguanosine. Virologica Sinica, 2018, 33, 538-544.	1.2	2
406	Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model. Brazilian Journal of Infectious Diseases, 2018, 22, 477-486.	0.3	2
407	AGK2, A SIRT2 Inhibitor, Inhibits Hepatitis B Virus Replication <i>In Vitro</i> And <i>In Vivo</i>. International Journal of Medical Sciences, 2018, 15, 1356-1364.	1.1	40
408	Use of a Fluorescent Analogue of a HBV Core Protein-Directed Drug To Interrogate an Antiviral Mechanism. Journal of the American Chemical Society, 2018, 140, 15261-15269.	6.6	10
409	High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China. Intervirology, 2018, 61, 123-132.	1.2	7
410	Molecular Characterization of Near Full-Length Genomes of Hepatitis B Virus Isolated from Predominantly HIV Infected Individuals in Botswana. Genes, 2018, 9, 453.	1.0	10
411	Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes. Virology, 2018, 525, 48-61.	1.1	20
412	Virology and Pathogenesis of Hepatitis B. , 2018, , 464-473.e5.		1
413	A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action. PLoS Neglected Tropical Diseases, 2018, 12, e0006629.	1.3	55
414	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	41
415	Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction. PLoS ONE, 2018, 13, e0197664.	1.1	40
416	The Medicinal Chemistry of Antihepatitis Agents II. , 2018, , 97-131.		1

#	ARTICLE	IF	CITATIONS
417	Developments in Cell-Penetrating Peptides as Antiviral Agents and as Vehicles for Delivery of Peptide Nucleic Acid Targeting Hepadnaviral Replication Pathway. <i>Biomolecules</i> , 2018, 8, 55.	1.8	14
418	Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide. <i>Biochemical and Biophysical Research Communications</i> , 2018, 501, 820-825.	1.0	9
419	Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. <i>Antiviral Research</i> , 2018, 158, 185-198.	1.9	53
420	Comparison of antiviral resistance across acute and chronic viral infections. <i>Antiviral Research</i> , 2018, 158, 103-112.	1.9	59
421	In Silico Analysis of Hepatitis B Virus Occult Associated Mutations in Botswana Using a Novel Algorithm. <i>Genes</i> , 2018, 9, 420.	1.0	5
423	Sanguisorba officinalis extract, ziyuglycoside I, and II exhibit antiviral effects against hepatitis B virus. <i>European Journal of Integrative Medicine</i> , 2018, 20, 165-172.	0.8	9
424	Hepatitis B Vaccines. , 2018, , 342-374.e17.		13
425	Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <i>Current Hepatology Reports</i> , 2019, 18, 363-369.	0.4	0
426	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 93-159.	4.5	171
427	Nucleic acid vaccines for hepatitis B and C virus. <i>Infection, Genetics and Evolution</i> , 2019, 75, 103968.	1.0	11
428	Stem Cell-Derived Hepatocyte-Like Cells as Model for Viral Hepatitis Research. <i>Stem Cells International</i> , 2019, 2019, 1-11.	1.2	11
429	Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 940-954.	1.9	9
430	Structure-Guided Approach to Identify Potential Inhibitors of Large Envelope Protein to Prevent Hepatitis B Virus Infection. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-14.	1.9	2
431	A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3307.	1.2	27
432	The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. <i>Microbial Pathogenesis</i> , 2019, 134, 103598.	1.3	1
433	Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs. <i>Virologica Sinica</i> , 2019, 34, 377-385.	1.2	3
434	Virological Factors Involved in AECHB. , 2019, , 119-157.		0
435	Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP. <i>Scientific Reports</i> , 2019, 9, 8462.	1.6	18

#	ARTICLE	IF	CITATIONS
437	<p>&Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications</p>. Infection and Drug Resistance, 2019, Volume 12, 977-987.	1.1	5
438	Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. Emerging Microbes and Infections, 2019, 8, 354-365.	3.0	15
439	Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate. Antiviral Research, 2019, 165, 47-54.	1.9	5
440	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. Journal of Hepatology, 2019, 71, 35-44.	1.8	29
441	Decellularized human liver scaffold-based three-dimensional culture system facilitate hepatitis B virus infection. Journal of Biomedical Materials Research - Part A, 2019, 107, 1744-1753.	2.1	12
442	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	3.7	342
443	Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes, 2019, 10, 260.	1.0	21
444	Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients. Antiviral Research, 2019, 164, 131-138.	1.9	8
445	Genotype and Serotype Identification of Hepatitis B Virus in Chronic Hepatitis B Patients Treated with Telbivudine. Journal of Physics: Conference Series, 2019, 1374, 012025.	0.3	0
446	Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis. BioMed Research International, 2019, 2019, 1-8.	0.9	21
447	HBV antigen and DNA loss from mouse serum is associated with novel vaccine-induced HBV surface antigen-specific cell-mediated immunity and cytokine production. Antiviral Research, 2019, 161, 20-27.	1.9	4
448	Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naïve chronically infected patients. VirusDisease, 2019, 30, 219-226.	1.0	4
449	Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues. Journal of Viral Hepatitis, 2019, 26, 278-286.	1.0	5
450	Paediatric chronic hepatitis B virus infection: are children too tolerant to treat?. Acta Paediatrica, International Journal of Paediatrics, 2019, 108, 1144-1150.	0.7	6
451	Synthesis and evaluation of the anti-hepatitis B virus activity of 4-azido-thymidine analogs and 4-azido-2-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 518-529.	0.4	2
453	Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis. Microbial Pathogenesis, 2020, 139, 103912.	1.3	1
454	A prognostic model for hepatitis B acute-to-chronic liver failure patients treated using a plasma exchange-centered liver support system. Journal of Clinical Apheresis, 2020, 35, 94-103.	0.7	9
455	Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphtropism in Antiviral Treatment and Oncogenesis. Microorganisms, 2020, 8, 1470.	1.6	15

#	ARTICLE	IF	CITATIONS
456	In vitro inhibition effects of hepatitis B virus by dandelion and taraxasterol. <i>Infectious Agents and Cancer</i> , 2020, 15, 44.	1.2	24
457	New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation. <i>Cells</i> , 2020, 9, 2430.	1.8	21
458	Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression. <i>Hepatology International</i> , 2020, 14, 973-984.	1.9	4
459	Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(t)ide Analogues. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2407-2416.	1.1	2
460	COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B. <i>Diagnostics</i> , 2020, 10, 491.	1.3	6
461	Hepatitis B Virus preS/S Truncation Mutant rtM204I/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGF β . <i>International Journal of Molecular Sciences</i> , 2020, 21, 6366.	1.8	6
462	Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region. <i>Frontiers in Microbiology</i> , 2020, 11, 616023.	1.5	29
463	Establishment of a system for finding inhibitors of μ RNA binding with the HBV polymerase. <i>Genes To Cells</i> , 2020, 25, 523-537.	0.5	4
464	HBV variants are common in the "immune-tolerant" phase of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1061-1070.	1.0	8
465	HBV replication inhibitors. <i>Antiviral Research</i> , 2020, 179, 104815.	1.9	37
466	The evolution and clinical impact of hepatitis B virus genome diversity. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 618-634.	8.2	107
467	Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing. <i>Journal of Clinical Virology</i> , 2020, 129, 104483.	1.6	9
468	HBV induced hepatocellular carcinoma and related potential immunotherapy. <i>Pharmacological Research</i> , 2020, 159, 104992.	3.1	57
469	Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. <i>Liver International</i> , 2020, 40, 1564-1577.	1.9	4
470	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	6.1	20
471	Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus. <i>Virus Evolution</i> , 2020, 6, veaa006.	2.2	4
472	Hepatitis B virus genotyping, detection of reverse transcriptase resistance and immune escape mutations in persons with chronic hepatitis B from Croatia. <i>Molecular and Experimental Biology in Medicine</i> , 2020, 3, 23-28.	0.1	1
473	Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ56136379 monotherapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1127-1137.	1.0	12

#	ARTICLE	IF	CITATIONS
474	Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. <i>Journal of Hepatology</i> , 2020, 73, 40-51.	1.8	53
475	Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. <i>Hepatology Research</i> , 2020, 50, 892-923.	1.8	66
476	Difluoromethylornithine, a Decarboxylase 1 Inhibitor, Suppresses Hepatitis B Virus Replication by Reducing HBc Protein Levels. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 158.	1.8	7
477	Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature Mutation in Treated Chronic Hepatitis B Patients. <i>Hepatology</i> , 2021, 73, 41-52.	3.6	57
478	HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals. <i>Antiviral Research</i> , 2021, 186, 104973.	1.9	28
479	Deep sequencing analysis of serum hepatitis B virus RNA during nucleot(s)ide analogue therapy. <i>Hepatology Research</i> , 2021, 51, 39-50.	1.8	4
480	Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients. <i>Journal of Infection in Developing Countries</i> , 2021, 15, 131-140.	0.5	0
481	Chronic Carriage of Hepatitis B Virus at the University Teaching Hospital Yalgado Ouedraogo: Therapeutic Aspects and Outcome in a Cohort of HBeAg+ Outpatients. <i>Open Journal of Epidemiology</i> , 2021, 11, 245-255.	0.2	0
482	Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes. <i>IScience</i> , 2021, 24, 101969.	1.9	17
483	Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 242-248.	1.3	11
484	HBV Core Protein Is in Flux between Cytoplasmic, Nuclear, and Nucleolar Compartments. <i>MBio</i> , 2021, 12, .	1.8	12
485	Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	2
486	Potential capacity of interferon- λ to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. <i>Gut Pathogens</i> , 2021, 13, 22.	1.6	10
487	Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1110-1120.	1.0	12
488	Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters. <i>Frontiers in Microbiology</i> , 2021, 12, 665184.	1.5	20
489	Molecular and computational analysis of natural drug resistance mutations among Moroccan chronic hepatitis B carriers. <i>Gene Reports</i> , 2021, 23, 101197.	0.4	0
491	Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations. <i>Journal of Virology</i> , 2021, 95, e0240120.	1.5	3
492	Hepatitis B virus-host interactions and novel targets for viral cure. <i>Current Opinion in Virology</i> , 2021, 49, 41-51.	2.6	23

#	ARTICLE	IF	CITATIONS
493	Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-8.	0.8	4
494	Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia. Journal of Clinical and Experimental Hepatology, 2022, 12, 144-154.	0.4	3
495	Efficient Inhibition of Hepatitis B Virus (HBV) Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors during Infection. Antimicrobial Agents and Chemotherapy, 2021, 65, e0146021.	1.4	11
496	Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs. Journal of Gastroenterology, 2021, 56, 1008-1021.	2.3	3
497	Molecular Virology and Life Cycle of Hepatitis B Virus. , 2021, , 1-27.		2
498	Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. , 2021, , 375-410.		0
499	Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection. The Cochrane Library, 0, , .	1.5	6
501	Hepatitis B Virus Drug Resistance. , 2017, , 1227-1242.		10
502	Hepatitis B Viruses. , 2017, , 309-331.		2
503	Present and Future Therapies for Chronic Hepatitis B. Advances in Experimental Medicine and Biology, 2020, 1179, 137-186.	0.8	32
504	Hepatitis B-related glomerulonephritis and optimization of treatment. Expert Review of Gastroenterology and Hepatology, 2020, 14, 113-125.	1.4	7
505	Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment. Journal of General Virology, 2015, 96, 3302-3312.	1.3	11
506	Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome. Journal of General Virology, 2018, 99, 1103-1114.	1.3	12
507	A peptide-based inhibitor of gp96 suppresses HBsAg expression and HBV replication by upregulation of p53. Journal of General Virology, 2019, 100, 1241-1252.	1.3	7
508	Investigating the impact of hepatitis B virus surface gene polymorphism on antigenicity using ex vivo phenotyping. Journal of General Virology, 2012, 93, 2473-2479.	1.3	13
511	Susceptibility Test Methods: Viruses. , 0, , 1913-1931.		1
512	Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms. Wellcome Open Research, 2020, 5, 151.	0.9	10
513	Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature. World Journal of Clinical Cases, 2018, 6, 671-674.	0.3	7

#	ARTICLE	IF	CITATIONS
514	Association of Preexisting Drug-Resistance Mutations and Treatment Failure in Hepatitis B Patients. PLoS ONE, 2013, 8, e67606.	1.1	8
515	Evidence for Multiple Distinct Interactions between Hepatitis B Virus P Protein and Its Cognate RNA Encapsidation Signal during Initiation of Reverse Transcription. PLoS ONE, 2013, 8, e72798.	1.1	9
516	Pre-Existing Mutations in Reverse Transcriptase of Hepatitis B Virus in Treatment-Naive Chinese Patients with Chronic Hepatitis B. PLoS ONE, 2015, 10, e0117429.	1.1	18
517	Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance. PLoS ONE, 2015, 10, e0136728.	1.1	18
518	HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathogens, 2017, 13, e1006658.	2.1	105
519	MicroRNAs as Important Players in Host-hepatitis B Virus Interactions. Journal of Clinical and Translational Hepatology, 2015, 3, 149-61.	0.7	17
520	Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment: A Long-term Cohort Study. Journal of Clinical and Translational Hepatology, 2018, 6, 1-7.	0.7	3
522	Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. Memorias Do Instituto Oswaldo Cruz, 2012, 107, 317-325.	0.8	12
523	Current Trends of Combination Therapy in Chronic Hepatitis B Management in China. Archives of Hepatitis Research, 2015, 1, 001-004.	0.4	1
524	Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing. Oncotarget, 2016, 7, 70264-70275.	0.8	7
525	Design, Synthesis and Biological Evaluation of Caudatin Analogs as Potent Hepatitis B Virus Inhibitors. Medicinal Chemistry, 2015, 11, 165-179.	0.7	5
526	A case report of successful therapy with tenofovir for a multi-drug resistant chronic hepatitis B patient complicated with malignant lymphoma. Acta Hepatologica Japonica, 2012, 53, 35-41.	0.0	1
527	Guidelines for the management of hepatitis B virus infection. Acta Hepatologica Japonica, 2013, 54, 402-472.	0.0	4
528	Coordinated evolution of the hepatitis B virus polymerase. In Silico Biology, 2011, 11, 175-82.	0.4	7
529	HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data. Clinical and Molecular Hepatology, 2013, 19, 409.	4.5	7
530	Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Clinical and Molecular Hepatology, 2014, 20, 274.	4.5	3
531	Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World Journal of Gastroenterology, 2011, 17, 2945.	1.4	5
532	Quantification of HBsAg: Basic virology for clinical practice. World Journal of Gastroenterology, 2011, 17, 283.	1.4	38

#	ARTICLE	IF	CITATIONS
533	Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis. World Journal of Gastroenterology, 2012, 18, 6290.	1.4	12
534	Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World Journal of Gastroenterology, 2012, 18, 6437.	1.4	5
535	Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World Journal of Gastroenterology, 2012, 18, 7149.	1.4	19
536	Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World Journal of Gastroenterology, 2014, 20, 5708.	1.4	41
537	Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates. World Journal of Gastroenterology, 2014, 20, 17100.	1.4	2
538	Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World Journal of Gastroenterology, 2015, 21, 10290.	1.4	14
539	Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World Journal of Gastroenterology, 2015, 21, 10874.	1.4	14
540	Roles of hepatocyte nuclear factors in hepatitis B virus infection. World Journal of Gastroenterology, 2016, 22, 7017.	1.4	42
541	Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?. World Journal of Gastroenterology, 2018, 24, 1825-1838.	1.4	11
542	Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World Journal of Gastroenterology, 2018, 24, 3488-3499.	1.4	31
543	Increased Occurrence of Mutant rtI233V of HBV in Patients Receiving Adefovir Therapy. Antiviral Therapy, 2016, 21, 9-16.	0.6	10
544	Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi Journal of Gastroenterology, 2015, 21, 245.	0.5	16
545	Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone. Saudi Journal of Gastroenterology, 2016, 22, 37.	0.5	5
546	Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. World Journal of Hepatology, 2012, 4, 43.	0.8	28
547	Variations and mutations in the hepatitis B virus genome and their associations with clinical characteristics. World Journal of Hepatology, 2015, 7, 583.	0.8	27
548	Clinical relevance of hepatitis B virus variants. World Journal of Hepatology, 2015, 7, 1086.	0.8	36
549	Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray. Gut and Liver, 2018, 12, 331-341.	1.4	4
550	A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model. Hepatitis Monthly, 2016, 16, e37435.	0.1	7

#	ARTICLE	IF	CITATIONS
551	Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan. <i>PeerJ</i> , 2019, 7, e6583.	0.9	8
552	Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B. <i>Gut and Liver</i> , 2010, 4, 212-218.	1.4	3
556	HBV Therapy and the Problem of Drug Resistance. , 2014, , 1-15.		0
557	Oxidative Stress in Chronic Viral Hepatitis. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2015, , 241-277.	0.4	0
558	Receptor for Hepatitis B and D Virus. <i>Korean Journal of Medicine</i> , 2015, 89, 35.	0.1	0
559	Hepatitis B and D Viruses. , 0, , 1841-1858.		9
560	The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns and Mechanisms. , 2017, , 565-577.		1
561	SELECTING THE MANAGEMENT OF PATIENTS WITH CHRONIC HEPATITIS B AFTER THE COMPLETION OF THE LONG-TERM ANTIVIRAL THERAPY. <i>Jurnal Infektologi</i> , 2018, 10, 108-114.	0.1	0
562	Effectiveness and Tolerance of Tenofovir Disoproxil Fumarate in Sub-Saharan Viral B Cirrhotic Patients. <i>Open Journal of Gastroenterology</i> , 2019, 09, 43-47.	0.1	0
563	Design and Synthesis of 4'-Cyano Dideoxy Isonucleosides and Their Activity against HIV-1 and HBV. <i>Heterocycles</i> , 2020, 100, 1599.	0.4	1
564	Blocking neddylation elicits antiviral effect against hepatitis B virus replication. <i>Molecular Biology Reports</i> , 2022, 49, 403-412.	1.0	3
565	Quercetin and its derivatives as antiviral potentials: A comprehensive review. <i>Phytotherapy Research</i> , 2022, 36, 266-278.	2.8	164
566	The Hepatitis B Virus Nucleocapsid "Dynamic Compartment for Infectious Virus Production and New Antiviral Target. <i>Biomedicines</i> , 2021, 9, 1577.	1.4	25
567	Hepatitis B Virus. , 2020, , 255-272.		0
568	Havachoobe (<i>Onosma dichroanthum Boiss</i>) Root Extract Decreases the Hepatitis B Virus Surface Antigen Secretion in the PLC/PRF/5 Cell Line. <i>Intervirology</i> , 2021, 64, 22-26.	1.2	6
570	Characterization of mutations in the reverse transcriptase region of hepatitis B virus in treated and untreated chronic hepatitis B patients. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 870-877.	0.7	0
571	Overview of anti-Hepatitis B virus agents. <i>Journal of Bacteriology and Virology</i> , 2020, 50, 141-149.	0.0	3
572	Induction of IFN- β cytokine response against hepatitis B surface antigen using melittin. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2014, 7, 108-17.	0.6	19

#	ARTICLE	IF	CITATIONS
573	Detection and analysis of resistance mutations of hepatitis B virus. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 9630-9.	1.3	9
574	Lessons learnt over two decades of vaccination against hepatitis B in Italy. <i>Journal of Preventive Medicine and Hygiene</i> , 2015, 56, E12-4.	0.9	4
575	Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection. <i>Iranian Journal of Basic Medical Sciences</i> , 2016, 19, 692-704.	1.0	11
576	An update on hepatitis B, D, and E viruses. <i>Topics in Antiviral Medicine</i> , 2014, 21, 157-63.	0.1	21
577	Antiviral Activity of <i>Cananga odorata</i> Against Hepatitis B Virus. <i>Kobe Journal of Medical Sciences</i> , 2019, 65, E71-E79.	0.2	5
578	Multifunctional antimicrobial materials: From rational design to biomedical applications. <i>Progress in Materials Science</i> , 2022, 125, 100887.	16.0	108
579	A nuanced role of the small loop of hepatitis B virus small envelope protein in virion morphogenesis and secretion. <i>Journal of Biomedical Science</i> , 2021, 28, 82.	2.6	1
580	The hepatitis B virus polymerase. <i>The Enzymes</i> , 2021, 50, 195-226.	0.7	5
581	Viral hepatitis in 2021: The challenges remaining and how we should tackle them. <i>World Journal of Gastroenterology</i> , 2022, 28, 76-95.	1.4	15
582	Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries. <i>Frontiers in Pediatrics</i> , 2021, 9, 809838.	0.9	3
583	Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy. <i>PLoS ONE</i> , 2022, 17, e0262516.	1.1	9
584	Naturally occurring HMGB1 inhibitor delineating the anti-hepatitis B virus mechanism of glycyrrhizin via in vitro and in silico studies. <i>Journal of Molecular Liquids</i> , 2022, 356, 119029.	2.3	3
585	Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa. <i>Viruses</i> , 2022, 14, 788.	1.5	3
588	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 1265-1275.	1.8	21
589	Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir. <i>Biomedicines</i> , 2022, 10, 1637.	1.4	1
590	Recent trends and advancements in electrochemiluminescence biosensors for human virus detection. <i>TrAC - Trends in Analytical Chemistry</i> , 2022, 157, 116727.	5.8	37
591	From HIV to COVID-19, Molecular mechanisms of pathogens' trade-off and persistence in the community, potential targets for new drug development. <i>Bulletin of the National Research Centre</i> , 2022, 46, .	0.7	0
592	A Lamivudine/ Entecavir Resistance Mutations Among Treatment Naïve Chronic HBV Infected Patients Mashhad, Iran. <i>Iranian Journal of Medical Microbiology</i> , 2022, 16, 376-382.	0.1	1

#	ARTICLE	IF	CITATIONS
593	Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies. <i>Viruses</i> , 2022, 14, 2404.	1.5	8
594	Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated with Nucleos(t)ide Analogues. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	3
595	Molecular and Genetic Characterization of Hepatitis B Virus (HBV) among Saudi Chronically HBV-Infected Individuals. <i>Viruses</i> , 2023, 15, 458.	1.5	4
596	Virtual Screening of Hepatitis B Virus Pre-Genomic RNA as a Novel Therapeutic Target. <i>Molecules</i> , 2023, 28, 1803.	1.7	2
600	Hepatitis B Vaccines. , 2023, , 389-432.e21.		0